nl_e17

76 MMWR May 10, 2002
58. Larsson PG, Platz-Christensen JJ, Forsum U, Pahlson C. Clue cells in
predicting infections after abdominal hysterectomy. Obstet Gynecol
1991;77:450–2.
59. Newton ER, Prihoda TJ, Gibbs RS. A clinical and microbiologic analysis
of risk factors for puerperal endometritis. Obstet Gynecol 1990;75:402–6.
60. Soper DE, Bump RC, Hurt WG. Bacterial vaginosis and trichomoniasis
vaginitis are risk factors for cuff cellulitis after abdominal hysterectomy.
Am J Obstet Gynecol 1990;163:1016–21.
61. Watts DH, Krohn MA, Hillier SL, Eschenbach DA. Bacterial vaginosis
as a risk factor for post-cesarean endometritis. Obstet Gynecol
1990;75:52–8.
62. Silver HM, Sperling RS, St. Clair PJ, Gibbs RS. Evidence relating
bacterial vaginosis to intraamniotic infection. Am J Obstet Gynecol
1989;161:808–12.
63. Bjornerem A, Aghajani E, Maltau JM, Moi H. Occurrence of bacterial
vaginosis among abortion seekers. Tidsskrift for Den Norske
Laegeforening 1997;117:1282–4.
64. Hamark B, Forssman L. Postabortal endometritis in chlamydia-negative
women—association with preoperative clinical signs of infection.
Gynecol Obstet Invest 1991;31:102–5.
65. Larsson PG, Bergman B, Forsum U, Platz-Christensen JJ, Pahlson C.
Mobiluncus and clue cells as predictors of PID after first-trimester
abortion. Acta Obstetrica et Gynecologica Scandinavica 1989;68:217–20.
66. Hillier SL, Martius J, Krohn M, Kiviat N, Holmes KK, Eschenbach
DA. A case-control study of chorioamnionic infection and histologic
chorioamnionitis in prematurity. New Engl J Med 1998;319:972–8.
67. Livengood CH, III, Soper DE, Sheehan KL, et al. Comparison of oncedaily
and twice-daily dosing of 0.75% metronidazole gel in the
treatment of bacterial vaginosis. Sex Transm Dis 1999;26:137–42.
68. Sobel J, Peipert JF, McGregor JA, et al. Efficacy of clindamycin vaginal
ovule vs. clindamycin vaginal cream in bacterial vaginosis. Infect Dis
Obstet Gynecol 2002 (in press).
69. Moi H, Erkkola R, Jerve F, et al. Should male consorts of women with
bacterial vaginosis be treated? Genitourin Med 1989;65:263–8.
70. Colli E, Landoni M, Parazzini F, et al. Treatment of male partners and
recurrence of bacterial vaginosis: a randomised trial. Genitourin Med
1997;73:267–70.
71. Vejtorp M, Bollerup AC, Vejtorp L, et al. Bacterial vaginosis: a doubleblind
randomized trial of the effect of treatment of the sexual partner.
Br J Obstet Gynaecol 1988;95:920–6.
72. McGregor JA, French JI, Jones W, et al. Bacterial vaginosis is associated
with prematurity and vaginal fluid mucinase and sialidase: results
of a controlled trial of topical clindamycin cream. Am J Obstet Gynecol
1994;170:1048–59.
73. Joesoef MR, Hillier SL, Wiknjosastro G, et al. Intravaginal clindamycin
treatment for bacterial vaginosis: effects on preterm delivery and low
birth weight. Am J Obstet Gynecol 1995;173:1527–31.
74. Vermeulen GM, Bruinse HW. Prophylactic administration of
clindamycin 2% vaginal cream to reduce the incidence of spontaneous
preterm birth in women with an increased recurrence risk: a randomised
placebo-controlled double-blind trial. Br J Obstet Gynaecol
1999;106:652–7.
75. Caro-Paton T, Carvajal A, Martin de Diego I, Martin-Arias LH, Alvarez
Requejo A. Is metronidazole teratogenic? A meta-analysis. Br J Clin
Pharmacol 1997;44:179–82.
76. Burtin P, Taddio A, Ariburnu O, Einarson TR, Koren G. Safety of
metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol
1995;172:525–9.
77. Piper JM, Mitchel EF, Ray WA. Prenatal use of metronidazole and
birth defects: no association. Obstet Gynecol 1993;82:348–52.
78. Carey JC, Klebanoff MA, Hauth JC, et al. Metronidazole to prevent
preterm delivery in pregnant women with asymptomatic bacterial
vaginosis. New Engl J Med 2000;342:534–40.
79. Hay PE, Ugwumadu AHN, Jeffrey I, Manvonda JT. Oral clindamycin
prevents spontaneous preterm birth and mid trimester miscarriage in
pregnant women with bacterial vaginosis. Int J STD AIDS
2001;12(Suppl 2):70–1.
80. Pearlman MD, Yashar C, Ernst S, Solomon W. An incremental dosing
protocol for women with severe vaginal trichomoniasis and adverse
reactions to metronidazole. Am J Obstet Gynecol 1996;174:934–6.
81. Klebanoff MA, Carey JC, Hauth JC, et al. Failure of metronidazole to
prevent preterm delivery among pregnant women with asymptomatic
Trichomonas vaginalis infection. New Engl J Med 2001;345:487–93.
82. Walker CK, Kahn JG, Washington AE, Peterson HB, Sweet RL.
Pelvic inflammatory disease: meta-analysis of antimicrobial regimen
efficacy. J Infect Dis 1993;168:969–78.
83. Matsuda S. Clinical study of levofloxacin (LVFX) on the infectious
diseases in the field of obstetrics and gynecology. Chemotherapy
1992;40:311–23.
84. Martens MG, Gordon S, Yarborough DR, Faro S, Binder D, Berkeley
A. Multicenter randomized trial of ofloxacin versus cefoxitin and doxycycline
in outpatient treatment of pelvic inflammatory disease. South
Med J 1993;86:604–10.
85. Peipert JF, Sweet RL, Kahn J, Reilly-Gauvin K. Evaluation of ofloxacin
in the treatment of laparoscopically documented acute pelvic inflammatory
disease (salpingitis). Infect Dis Obstet Gynecol 1999;7:138–44.
86. Walker CK, Workowski KA, Washington AE, Soper D, Sweet RL.
Anaerobes in pelvic inflammatory disease: implications for the Centers
for Disease Control and Prevention’s guidelines for treatment of sexually
transmitted diseases. Clin Infect Dis 1999;28(Suppl 1):S29–S36.
87. Witte EH, Peters AA, Smit IB, van der Linden MC, Mouton RP, van
der Meer JW, van Erp EJ. A comparison of pefloxacin/metronidazole
and doxycycline/metronidazole in the treatment of laparoscopically
confirmed acute pelvic inflammatory disease. Eur J Obstet Gynecol
Reprod Biol 1993;50:153–8.
88. Ridgway GL, Bevan C, Siddle N. Azithromycin with or without metronidazole
compared with cefoxitin, doxycycline and metronidazole
in the treatment of laparoscopy confirmed acute pelvic inflammatory
disease [Abstract]. In: Proceedings of the 11th International Meeting
of the International Society for STD Research, New Orleans. Fort
Lee, New Jersey: International Society for STD Research, 1995.
89. Cohen CR, Sinei S, Reilly M, et al. Effect of human immunodeficiency
virus type 1 infection upon acute salpingitis: a laparoscopic study.
J Infect Dis 1998;178:1352–8.
90. Bukesi EA, Cohen CR, Stevens CE, et al. Effects of human immunodeficiency
virus 1 infection on microbial origins of pelvic inflammatory
disease and on efficacy of ambulatory oral therapy. Am J Obstet
Gynecol 1999;18:1374–81.
91. Irwin KL, Moorman AC, O’Sullivan MJ, et al. Influence of human
immunodeficiency virus infection on pelvic inflammatory disease.
Obstet Gynecol 2000;95:525–34.
92. Kamb ML. Cervical cancer screening of women attending sexually transmitted
diseases clinics. Clin Infect Dis 1995;20(Suppl 1): S98–S103.
93. American Cancer Society. Guidelines for the cancer related checkup.
Atlanta, Georgia: American Cancer Society, 1998.